Powers Jacquelyn M, Buchanan George R
Pediatric Hematology-Oncology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9063, USA.
Pediatric Hematology-Oncology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9063, USA.
Hematol Oncol Clin North Am. 2014 Aug;28(4):729-45, vi-vii. doi: 10.1016/j.hoc.2014.04.007. Epub 2014 Jun 2.
Iron deficiency anemia (IDA) is a common hematologic condition, affecting a substantial proportion of the world's women and young children. Optimal management of IDA requires an accurate diagnosis, identification and correction of the underlying cause, provision of medicinal iron therapy, and confirmation of treatment success. There are limited data to support current treatment approaches regarding oral iron preparation, dosing, monitoring, and duration of therapy. New intravenous iron agents have improved safety profiles, which may foster their increased utilization in the treatment of patients with IDA. Clinical trials focused on improving current treatment standards for IDA are sorely needed.
缺铁性贫血(IDA)是一种常见的血液系统疾病,影响着世界上相当一部分妇女和儿童。IDA的最佳管理需要准确诊断、识别并纠正潜在病因、提供铁剂药物治疗以及确认治疗成功。关于口服铁剂的制备、剂量、监测和治疗持续时间,支持当前治疗方法的数据有限。新型静脉铁剂具有更好的安全性,这可能促使其在IDA患者治疗中的使用增加。迫切需要开展专注于改善IDA当前治疗标准的临床试验。